Drug Type Synthetic peptide, Cyclic Peptide |
Synonyms BIM-22493, CAM 4072, CAM-4072 + [3] |
Target |
Action agonists |
Mechanism MC4R agonists(Melanocortin receptor 4 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (25 Nov 2020), |
RegulationPriority Review (United States), Breakthrough Therapy (United States), Orphan Drug (United States), Orphan Drug (European Union), PRIME (European Union), Orphan Drug (Japan), Priority Review (Canada), Rare Pediatric Disease (United States) |
Molecular FormulaC51H72N18O11S2 |
InChIKeyBAJXLDXHOOSXOU-GZRAWZNHSA-N |
CAS Registry1504602-49-6 |

| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Hypothalamic obesity | United States | 19 Mar 2026 | |
| Bardet-Biedl Syndrome | United States | 16 Jun 2022 | |
| Proopiomelanocortin Deficiency | European Union | 16 Jul 2021 | |
| Proopiomelanocortin Deficiency | Iceland | 16 Jul 2021 | |
| Proopiomelanocortin Deficiency | Liechtenstein | 16 Jul 2021 | |
| Proopiomelanocortin Deficiency | Norway | 16 Jul 2021 | |
| Obesity | United States | 25 Nov 2020 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Combined Pituitary Hormone Deficiency | Phase 3 | United States | 23 Sep 2025 | |
| Combined Pituitary Hormone Deficiency | Phase 3 | United Kingdom | 23 Sep 2025 | |
| Optic Nerve Hypoplasia | Phase 3 | United States | 23 Sep 2025 | |
| Optic Nerve Hypoplasia | Phase 3 | United Kingdom | 23 Sep 2025 | |
| Septo-Optic Dysplasia | Phase 3 | United States | 23 Sep 2025 | |
| Septo-Optic Dysplasia | Phase 3 | United Kingdom | 23 Sep 2025 | |
| Pediatric Obesity | Phase 3 | United States | 26 Apr 2022 | |
| Pediatric Obesity | Phase 3 | Canada | 26 Apr 2022 | |
| Pediatric Obesity | Phase 3 | France | 26 Apr 2022 | |
| Pediatric Obesity | Phase 3 | Germany | 26 Apr 2022 |
Phase 3 | 142 | Setmelanotide 0.5 mg subcutaneously once daily | unnqiszwtj(ggpwbocpru) = aehdaymaqz ioswvgyzme (kobkoefyfy ) View more | Positive | 14 Nov 2026 | ||
Placebo | unnqiszwtj(gnmwpasedu) = iibsunjeso zhzdgrqcmb (ipkshedwdt ) View more | ||||||
Phase 3 | 142 | vugzascego(ufqkptpgxr) = During Year 1, the most commonly reported AEs (≥30% in the SET arm) were skin hyperpigmentation (56.4% SET vs. 8.3% PBO), nausea (55.3% SET vs. 25.0% PBO), vomiting (38.3% SET vs. 18.8% PBO), and headache (36.2% SET vs. 31.3% PBO). During Year 2, the most common newly reported AEs (≥15% in PBO-SET arm) were skin hyperpigmentation (6.4% SET-SET vs 43.8% PBO-SET), headache (10.6% SET-SET vs 25.0% PBO-SET), diarrhea (7.4% SET-SET vs 18.8% PBO-SET), and vomiting (7.4% SET-SET vs 18.8% PBO-SET). ubbtrtunqv (shrlfdieks ) | Positive | 14 Nov 2026 | |||
Placebo | |||||||
Phase 3 | 142 | ogsaqtmmqp(dyzjhhkxga) = rgwcoomzbw crlrdfvqwo (wjjcdzcpkv ) View more | Positive | 14 Nov 2026 | |||
Placebo | ogsaqtmmqp(dyzjhhkxga) = wzjrukkdxw crlrdfvqwo (wjjcdzcpkv ) View more | ||||||
Phase 3 | 120 | hqfywgkgjl(akaxxvlrgk) = dmpxrtricl itoqwwpfoe (kuncluwvmf ) View more | Positive | 14 Nov 2026 | |||
Not Applicable | Obesity MC4R variants | 100 | ctoytaejiv(twbtfowavx) = hhxgvwnlrm ckekhssuwx (pnowzwknsk ) View more | Positive | 14 Nov 2026 | ||
Phase 3 | 120 | Setmelanotide 1.5 to 3.0 mg | kdgabphoqt(pebdxtbpyk) = nsbwlpcslp qnywdqdats (yidwqyimdx, -19.3 to -13.8) View more | Positive | 09 Jul 2026 | ||
Placebo | kdgabphoqt(pebdxtbpyk) = yuiseklfsf qnywdqdats (yidwqyimdx, -0.6 to 7.2) View more | ||||||
Phase 2 | 14 | sgplekkagt(vutbckrqoe) = srlgmrebfg jdqnmbptxe (ejpgtcoqsh ) | Positive | 15 Jun 2026 | |||
Not Applicable | 22 | mgpciipvqh(zgyzbjauuj) = oqhjthdsvt whooufolrl (joplbrhbgj, 0.6) View more | Positive | 14 Jun 2026 | |||
Phase 3 | 110 | (pediatric participants) | hrqclqdwce(uwbqmbtblr) = Common adverse events that were reported in >30% of the setmelanotide group were skin hyperpigmentation (setmelanotide, 55.6% vs placebo, 7.7%), nausea (50.6% vs 30.8%), vomiting (39.5% vs 17.9%), and headache (38.3% vs 30.8%). ynsgdatddl (yylzfkhsoc ) | Positive | 14 Jun 2026 | ||
(adult participants) | |||||||
Phase 3 | 6 | foxfdvvnis(pqytavpuaw) = lciozsvmwf wtcldhqqtl (njuprytqkr ) | Positive | 13 Jun 2026 | |||
Placebo | foxfdvvnis(pqytavpuaw) = llpdsjopwl wtcldhqqtl (njuprytqkr ) |






